There are currently 96 clinical trials in Wilmington, North Carolina looking for participants to engage in research studies. Trials are conducted at various facilities, including PMG Research of Wilmington, LLC, GSK Investigational Site, PMG Research of Wilmington and New Hanover Regional Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)
NCT05772169
Recruiting
This is a Phase 4 study with 2 parts: Part 1 (Prevalence Phase) is non-interventional and will assess the prevalence of hypercortisolism in a population with difficult to control type 2 diabetes (T2D) (hemoglobin A1c ≥7.5%) despite receiving standard-of-care therapies. Part 2 (Treatment Phase) is a randomized, prospective, placebo-controlled, double-blind multi-center trial that will assess the safety and efficacy of mifepristone treatment in patients with hypercortisolism who have difficult to... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
05/24/2024
Locations: Site 059, Wilmington, North Carolina
Conditions: Hypercortisolism, Diabetes Mellitus, Type 2
Register for Updates
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
NCT06354660
Recruiting
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and inadequate glycemic control. The study will last about 11 months and may include up to 11 visits.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/24/2024
Locations: Accellacare - Wilmington - 1917 Tradd Court, Wilmington, North Carolina
Conditions: Diabetes Type 2
Register for Updates
A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease
NCT06226545
Recruiting
LASN01 is a novel, fully human antibody directed against the human IL-11 receptor being developed for treatment of patients with thyroid eye disease (TED). The primary and secondary objectives of this study are to evaluate the safety, efficacy, and pharmacokinetics of LASN01 administered IV in patients with TED with no prior anti-IGF-1R treatment or in patients with TED who have previously received teprotumumab treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/24/2024
Locations: Site 110, Wilmington, North Carolina
Conditions: Thyroid Eye Disease, Eye Diseases, Graves Ophthalmopathy, Graves Orbitopathy, Thyroid Associated Ophthalmopathy, Endocrine System Diseases, Orbital Diseases, Proptosis
Register for Updates
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873
Recruiting
The purpose of this study is to measure the efficacy and safety of baxdrostat/dapagliflozin in participants ≥ 18 years of age with CKD and HTN. This study consists of a screening, a 4-week dapagliflozin run-in period for participants naïve to SGLT2i at baseline; a 24-month double-blind period in which participants will receive either baxdrostat/dapagliflozin or dapagliflozin; and a 6-week open-label period in which all participants will discontinue baxdrostat/placebo and receive dapagliflozin al... Read More
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
05/22/2024
Locations: Research Site, Wilmington, North Carolina +1 locations
Conditions: Chronic Kidney Disease and Hypertension
Register for Updates
Algorithm Using LINQ Sensors for Evaluation And Treatment of Heart Failure
NCT04452149
Recruiting
The ALLEVIATE-HF study is a prospective, randomized, controlled, blinded, multi-site, interventional, investigational device exemption (IDE) pivotal study. The purpose of the study is to demonstrate the safety and efficacy of a patient management pathway that utilizes an integrated device diagnostic-based risk stratification algorithm to guide patient care in subjects with NYHA class II and III heart failure, and to demonstrate the safety of the Reveal LINQ™ system and procedure in the study pop... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/22/2024
Locations: Novant Health New Hanover Regional Medical Center, Wilmington, North Carolina
Conditions: Heart Failure NYHA Class II, Heart Failure NYHA Class III
Register for Updates
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
NCT06329401
Recruiting
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/21/2024
Locations: Accellacare, Wilmington, North Carolina
Conditions: Progressive Pulmonary Fibrosis
Register for Updates
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
NCT05523167
Recruiting
This study's purpose is to measure the treatment response from efgartigimod PH20 SC compared with placebo in participants with Idiopathic Inflammatory Myopathy (IIM). Participants with the IIM subtypes of dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), or certain other subtypes of polymyositis (PM; including antisynthetase syndrome [ASyS]) will be included in the study. Treatment response will be measured by Total improvement score (TIS). Additional information can be found on... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/17/2024
Locations: Carolina Arthritis Associates, Wilmington, North Carolina
Conditions: Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
Register for Updates
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
NCT05507203
Recruiting
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins,... Read More
Gender:
All
Ages:
16 years and above
Trial Updated:
05/16/2024
Locations: Wilmington Health, Wilmington, North Carolina
Conditions: Ulcerative Colitis
Register for Updates
Project Talk Trial: Engaging Underserved Communities in End-of-life Conversations
NCT04612738
Recruiting
Compared to the general population, individuals from underserved communities are more likely to receive low quality end-of-life care and unwanted, costly and burdensome treatments due in part to a lack of advance care planning (ACP; the process of discussing wishes for end-of-life care with loved ones/clinicians and documenting them in advance directives). This study will use existing, trusted, and respected social networks to evaluate two conversation-based tools intended to engage underserved... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/16/2024
Locations: Plaza on Princess, Wilmington, North Carolina
Conditions: Advance Care Planning, Advance Directives, Terminal Illness, Chronic Illness, Communication
Register for Updates
Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring
NCT05739123
Recruiting
The Relugolix Pregnancy Registry is a prospective, observational cohort study designed to evaluate the association between relugolix-containing therapy exposure during pregnancy and subsequent maternal, fetal, and infant outcomes. Data will be collected from enrolled pregnant women and the healthcare providers (HCPs) involved in their care or the care of their infants, if applicable.
Gender:
Female
Ages:
0 years and above
Trial Updated:
05/14/2024
Locations: PPD, Wilmington, North Carolina
Conditions: Pregnancy Related, Pregnancy Complications, Pregnancy, High Risk
Register for Updates
SUNOSI® (Solriamfetol) Pregnancy Registry
NCT06413420
Recruiting
The SUNOSI (solriamfetol) Pregnancy Registry is a prospective, multi-country, observational study to evaluate the safety of solriamfetol exposure during pregnancy in women with a diagnosis of narcolepsy or obstructive sleep apnea (OSA).
Gender:
Female
Ages:
All
Trial Updated:
05/09/2024
Locations: PPD, Inc., Wilmington, North Carolina
Conditions: Narcolepsy, Obstructive Sleep Apnea, Pregnant Women and Their Offspring
Register for Updates
Multicenter Study to Evaluate Corneal Neurosensory Abnormalities in Patients With Sjögren's Dry Eye
NCT06411132
Recruiting
Primary Objective - To assess the proportion of patients with Sjögren's dry eye who demonstrate impaired corneal sensitivity. Secondary Objectives To assess corneal sensitivity via Cochet-Bonnet esthesiometer. To assess tear secretion via Schirmer I test. To assess OPAS questionnaire results.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: Focus Eye Care, Wilmington, North Carolina
Conditions: Sjögren Syndrome, Dry Eye
Register for Updates